Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.52 |
| ▸ | ITGAV | P06756 | 16/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18968795 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL13107808 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL16946584 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL19605481 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL7743533 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL12808284 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL7743878 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL14885799 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL21475019 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL12547669 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVITGA5ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367065-B2 | Targeted polymeric prodrugs containing multifunctional linkers | ENZON PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233190-A1 | TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS | PAICS, FCGRT, DNPEP | ITGB3 565/4885ITGAV 398/4885ITGA5 421/4885 |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | PIGO, PHOSPHO1, PAICS | ITGB3 219/4885ITGAV 192/4885ITGA5 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.